Non-Small Cell Lung Cancer (NSCLC)

Preliminary data from the phase 1/2 TARGET-D 101 trial showed a manageable safety profile for VS-7375 across KRAS G12D–mutated solid tumors.

Investigators will share detailed results from the phase 3 SigVie-002 trial assessing sigvotatug vedotin in NSCLC at a future medical meeting.

Binimetinib tablets at 45 mg received tentative FDA approval for patients with melanoma and NSCLC.

A recommendation from the external data monitoring committee led to the discontinuation of the phase 3 KEYNOTE D46/EVOKE-03 study.

Cancer-related survival was similar among patients with PD-L1–positive or PD-L1–negative NSCLC who received durvalumab.

The FLAME trial showed osimertinib plus carboplatin/pemetrexed significantly improved PFS vs osimertinib monotherapy in ctDNA-persistent EGFR-mutant NSCLC.

The role of adjuvant immunotherapy remains unclear in this NSCLC population following data from the phase 3 ALCHEMIST trial.

Seven-year data from the CROWN study show improved PFS with lorlatinib over crizotinib among patients with ALK-positive non–small cell lung cancer.

The phase 3 HARMONi-6 trial showed ivonescimab plus chemotherapy significantly improved OS vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Data from the phase 3 LIBRETTO-432 study may support adjuvant selpercatinib as a new standard of care in this NSCLC population.

Data from the phase 1/1b CHRYSALIS-2 trial show enduring responses with amivantamab plus lazertinib in this EGFR-mutated NSCLC population.

The objective response rate was significantly higher with sac-TMT plus pembrolizumab vs pembrolizumab alone in the phase 3 OptiTROP-Lung05 trial.

The FDA has assigned a Prescription Drug User Fee Act date of November 27, 2026, for neladalkib in this ALK-positive non–small cell lung cancer population.

Developers intend to submit a supplemental new drug application for toripalimab/chemotherapy in resectable stage II or III NSCLC.

Approval of the FoundationOne CDx may help identify patients with NSCLC harboring MET exon 14 skipping alterations who are candidates for tepotinib.

Disease control was observed in all patients who received JNJ-1900 in part 1 of the phase 2 CONVERGE trial.

Data from the phase 1/2 SOHO-01 study support the supplemental new drug application for sevabertinib in this NSCLC population.

The safety profile of zoldonrasib appeared to be “superb” among patients with NSCLC harboring KRAS G12D mutations, said Jonathan Wesley Riess, MD, MS.

The FDA has set a Prescription Drug User Fee Act date of January 4, 2027, for approving taletrectinib in this ROS1-positive NSCLC population.

Updated findings from the TRUST-I and TRUST-II trials may reflect the importance of molecular testing in non–small cell lung cancer therapy.

Previous data presented at the 2026 AACR Annual Meeting demonstrate the efficacy of taletrectinib in ROS1-positive NSCLC harboring brain metastases.

Preliminary data from the phase 1/1b RMC-9805-001 study support continued development of zoldonrasib as a therapeutic strategy in this population.

Data from the phase 2 MATISSE trial could pave the way for CD39 and adenosine pathway inhibition in early-stage non–small cell lung cancer.

A numerical survival improvement was observed with ramucirumab plus pembrolizumab among those with squamous cell carcinoma in a phase 2 study.

Experts discussed the evolving landscape of EGFR-mutated NSCLC, focusing on the practice-changing results of the ADAURA and NeoADAURA trials.